ASN 004Alternative Names: MUC-1 cancer vaccine - Ascend Biopharmaceuticals
Latest Information Update: 10 Oct 2015
At a glance
- Originator Ascend Biopharmaceuticals
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer; Solid tumours
Most Recent Events
- 09 Oct 2015 Preclinical trials in Breast cancer and other Solid tumours in Australia (Parenteral)
- 09 Oct 2015 Ascend Biopharmaceuticals plans a phase Ib trial for Breast cancer (Early-stage disease) in Australia (Parenteral)